Farnesyl: Proteintransferase inhibitors as agents to inhibit tumor growth

BioFactors

Volumn 6, Issue 3, 1997, Pages 359-366

  Omer, Ch A ^a   Anthony, N J ^a   Buser Doepner, C A ^a   Burkhardt, A L ^a   DeSolms, S J ^a   Dinsmore, Ch J ^a   Gibbs, J B ^a   Hartman, G D ^a   Koblan, K S ^a   Lobell, R B ^a   Oliff, A ^a   Williams, T M ^a   Kohl, N B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ENZYME INHIBITOR; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0030668479     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520060306     Document Type: Article

References (37)

1. Rho proteins, J. Biol. Chem. 267 (1992), 20 033.
2. S.A. Armstrong et al., CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB, J. Biol. Chem. 270 (1995), 7864.
3. M. Barbacid, Ras genes, Ann. Rev. Biochem. 56 (1987), 779.
4. W.R. Bishop et al., Novel tricyclic inhibitors of farnesyl protein transferase, J. Biol. Chem. 270 (1995), 30 611.
5. J.L. Bos, Ras oncogenes in human cancer: A review, Cancer Res. 49 (1989), 4682.
6. P.J. Casey et al., p21 Ras is modified by a farnesyl isoprenoid, Proc. Natl. Acad. Sci. USA 86 (1989), 8323.
7. G.J. Clark and C.J. Der, Ras proto-oncogene activation in human malignancy, in: Cellular Cancer Markers, C.T. Garret and S. Sell, eds, Humana Press, Totowa, New Jersey, 1995, pp. 17-52.
8. S. Clarke, Protein isoprenylation and methylation at carboxyl-terminal cysteine residues, Ann. Rev. Biochem. 61 (1992), 355.
9. C. Evans-Trueblood, Y. Ohya and J. Rine, Genetic evidence for in vivo cross-specificity of the CAAX box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase, Mol. Cell. Biol. 13 (1993), 4260.
10. J.B. Gibbs et al., Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo, J. Biol. Chem. 268 (1993), 7617.
11. A.M. Garcia et al., Peptidomimetic inhibitors of Ras farnesylation and function in whole cells, J. Biol. Chem. 268 (1993), 18 415.
12. J.B. Gibbs, A. Oliff and N.E. Kohl, Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic, Cell 77 (1994), 175.
13. J.L. Goldstein et al., Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase, J. Biol. Chem. 266 (1991), 15 575.
14. G.L. James et al., Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells, Science 260 (1993), 1937.
15. G.L. James et al., Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras transformed Rat-I cells, but not in untransformed cells, J. Biol. Chem. 269 (1994), 27 705.
16. G.L. James et al., A prenylated protein of peroxisomes, J. Biol. Chem. 269 (1994), 14 182.
17. G.L. James, J.L. Goldstein and M.S. Brown, Polylysine and CVIM sequences of K-RasB dictates specificity of prenylation and confer resistance to benzodiazepine in vitro, J. Biol. Chem. 270 (1995), 6221.
18. G.L. James et al., Resistance of K-RasB v12 proteins to farnesyltransferase inhibitors in Rat1 cells, Proc. Natl. Acad. Sci. USA 93 (1996), 4454.
19. N.B. Kohl et al., Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor, Science 260 (1993), 1934.
20. N.B. Kohl et al., Farnesyltransferase inhibitors block the growth of Ras-dependent tumors in nude mice, Proc. Natl. Acad. Sci. USA 91 (1994), 9141.
21. N.B. Kohl et al., Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in Ras transgenic mice, Nat. Genet. 1 (1995), 792.
22. E.C. Lerner et al., Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyl transferase-I inhibitor, J. Biol. Chem. 270 (1995), 26 770.
23. E.C. Lerner et al., Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes, J. Biol. Chem. 270 (1995), 26 802.
24. P.F. Liebowitz, J.P. Davide and G.P. Prendergast, Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity, Mol. Cell. Biol. 15 (1995), 6613.
25. L. Lin, T. Dudler and M.H. Gelb, Purification of a protein palmitoyltransferase that acts on H-Ras protein and a C-terminal N-Ras peptide, J. Biol. Chem. 271 (1996), 23 269.
26. D.R. Lowy and B.M. Willumsen, Function and regulation of Ras, Ann. Rev. Biochem. 62 (1993), 851.
27. V. Manne et al., Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of Ras transformed cells, Oncogene 10 (1995), 1763.
28. S.L. Moores et al., Sequence dependence of protein isoprenylation, J. Biol. Chem. 266 (1991), 14 603.
29. T. Nagasu et al., Inhibition of human tumor xenograph growth by treatment with the farnesyl transferase inhibitor B956, Cancer Res. 55 (1995), 5310.
30. G.C. Prendergast and J.B. Gibbs, Pathways of Ras function: connections to the actin cytoskeleton, Adv. Cancer Res. 62 (1993), 190.
31. G.P. Prendergast et al., Farnesyltransferase inhibition causes morphological reversion of Ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton, Molec. Cell. Biol. 14 (1994), 4193.
32. L. Sepp-Lorenzino et al., A peptidomimetic inhibitor of farnesyl : protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines, Cancer Res. 55 (1995), 5302.
33. S. Shirasawa et al., Altered growth of human colon cancer cell lines disrupted at activated Ki-Ras, Science 260 (1993), 85.
34. E. Sinn et al., Coexpression of MMTV/v-Ha-Ras and MMTV/c-Myc genes in transgenic mice: synergistic action of oncogenes in vivo, Cell 49 (1987), 465.
35. J. Sun et al., Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion, Cancer Res. 55 (1995), 4243.
36. T.M. Williams et al., 2-substituted piperazines as constrained amino acids: applications to the synthesis of potent, noncarboxylic acid inhibitors of farnesyltransferase, J. Med. Chem. 39 (1996), 1345.
37. F.L. Zhang and P.J. Casey, Protein prenylation : molecular mechanisms and functional consequences, Ann. Rev. Biochem. 65 (1996), 21.